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1. Abstract 
 
Decreased peripheral insulin sensitivity in combination with reduced function and mass of 
insulin producing β cells are the main pathogenic factors of type-2 diabetes mellitus1-3. Recent 
studies suggest that increased activity of the mitogen-activated protein kinase (MAPK) c-jun 
N-terminal kinase (JNK) in response to inflammatory and metabolic stresses represents a 
central signal transduction event promoting peripheral insulin resistance4, 5. JNK activation 
also attenuates insulin production and secretion and increases apoptosis of islet cells6-8, 
several factors, which contribute to impaired glucose homeostasis in diabetic patients. The 
closely related MAPK p38 family consists of four members p38α (MAPK14), p38β 
(MAPK11), p38γ (MAPK12) and p38δ (MAPK13)9. However, the specific role of each 
isoform remains poorly understood. Here, we demonstrate that mice lacking p38δ (MAPK13) 
show improved glucose tolerance due to enhanced insulin secretion caused by increased 
insulin granule exocytosis in pancreatic β cells. Deletion of p38δ results in enhanced 
formation of vesicles at the Golgi apparatus. Conversely, expression of constitutively active 
p38δ promotes generation of tubular Golgi protrusions. Enhanced vesicle formation is 
associated with pronounced activation of protein kinase D (PKD), a critical step at the trans-
Golgi network (TGN) required for budding of secretory vesicles. Inhibition of PKD restores 
the Golgi integrity and is sufficient to reconstitute insulin secretion of p38δ-deficient islets 
and glucose tolerance in p38δ null mice. Hence, p38δ links TGN function to insulin secretion 
and might represent a novel therapeutic target in type-2 diabetes. 
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2. Synopsis  
 
Das Auftreten von Diabetes Mellitus II ist in den vergangenen zwei Jahrzehnten 
dramatisch angestiegen.  
In meiner Arbeit untersuchte ich die molekularen Mechanismen, die zur 
Entstehung von Diabetes II führen. Ich identifizierte ein Protein (p38δ) als 
Inhibitor der Insulinsekretion. p38δ ist damit ein mögliches Ziel für die 
Behandlung von Diabetes II.  
 5
3. Abbreviations 
  
ATP   adenosine tri-phosphate  
CNS   central nervous system 
CVD   cardiovascular disease 
DAG   diacylglycerol  
ER-stress  endoplasmic reticulum stress  
FFAs    free fatty acids 
ERK   extracellular regulated kinase 
GLP-1   glucagon like peptide 1  
GPCR   G protein coupled receptor  
GSK3   Glycogen-synthase kinase-3  
GTT   glucose tolerance test  
IGF-1   insulin-like growth factor 1  
INS1   rat insulinoma cell line 
IR   insulin receptor  
IRS   insulin receptor substrate 
ITT   insulin tolerance test  
JNK   c-jun N-terminal kinase 
LPS   lipopolysaccharide  
MAPK  Mitogen Activated Protein Kinase  
MIN6   murine insulinoma cell line 
MODY  maturity onset diabetes of the young  
NFκB   nuclear factor kappa B  
PKA   protein kinase A  
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PKD   protein kinase D 
TGN   trans-Golgi network  
TNFα   tumor necrosis factor α 
TLR   Toll-like receptor 
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4. Introduction 
 
4.1. Diabetes mellitus – general aspects 
 
 Diabetes mellitus represents one of the most common uncommunicable diseases 
affecting almost 6% of the world’s population. According to the International Diabetes 
Federation, the number of diabetic patients is predicted to reach 300 millions in 202510.  
 Diabetes is defined as a state in which carbohydrate and lipid metabolism is 
inappropriately regulated by insulin. This results in elevated fasting and postprandial glucose 
and eventually leads to multiple clinical complications11. There are two main forms of diabetes 
mellitus. Type-1 diabetes mellitus is well recognized as a condition of absolute insulin 
deficiency due to extensive autoimmune destruction of pancreatic β cells12. Type-2 diabetes 
mellitus is characterized by several metabolic defects, among which β cell secretory 
dysfunction and peripheral insulin resistance are considered as hallmarks of the disease13. 
Previously, type-2 diabetes was regarded as a distinct disease entity, but in reality, it is often a 
manifestation of a much broader underlying disorder called the metabolic syndrome – a cluster 
of cardiovascular disease (CVD) risk factors that, in addition to glucose intolerance, includes 
hyperinsulinaemia, dyslipidaemia, atherosclerosis, hypertension, visceral obesity, 
hypercoagulability and microalbuminuria14. The correlation of the occurrence of these 
conditions suggests a high interconnectivity of these traits and implies interdependent cellular 
and molecular mechanisms. 
Elevated plasma levels of glucose in type-2 diabetic individuals result from disruption of 
equilibrium between deposition of glucose in peripheral insulin-sensitive organs, mainly 
skeletal muscles and liver, absorption of carbohydrates and other nutrients in the 
gastrointestinal tract as well as output of glucose from the liver11. This equilibrium is regulated 
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mainly by two hormones: insulin, secreted from the pancreatic β cells to circulation during the 
state of high glucose plasma levels which promotes glucose deposition; in contrast, glucagon, 
secreted by pancreatic α cells during periods of fasting, promoting gluconeogenesis in the 
liver15. 
 As mentioned above, type-2 diabetes mellitus is mostly associated with visceral obesity. 
Obesity is caused by a dysbalance between energy intake and energy expenditure and results in 
energy deposition in form of fat in adipocytes. The mechanisms controlling energy intake 
involve both the control of nutrient uptake in the gut and the regulation of appetite, the latter of 
which is controlled centrally and involves a hormonal communication between the brain and 
peripheral tissues16. Energy expenditure occurs through physical activity (voluntary 
movements), basal metabolism (myriad of biochemical processes necessary to maintain life) 
and mainly in rodents through adaptive thermogenesis (energy dissipated in the form of heat in 
response to environmental changes)17. 
A causal contribution of obesity to type-2 diabetes mellitus is reflected by the fact that 
normalization of the body weight restores several metabolic disturbances. Body weight 
reduction therefore constitutes a main therapeutic goal in diabetic patients. As a consequence 
mechanisms controlling whole body energy homeostasis and adipose growth, build the focus of 
many research laboratories. Adipose accretion and the metabolic overload of adipocytes 
activates a number of stress-induced pathways to ultimately increase secretion of multiple 
insulin resistance factors including inflammatory mediators (TNFα, IL-6)18-20, free fatty acids 
(FFAs)15 and insulin desensitizing adiponectins such as for example resistin21. In the same time, 
adipose-derived insulin sensitizing factors such as adiponectin tend to be secreted in reduced 
amounts22. Several studies provided evidence that these factors are key in promoting or 
protecting against insulin resistance, respectively. Decreased peripheral insulin sensitivity 
initially is compensated by increased insulin production and secretion from pancreatic β cells. 
These adaptive mechanisms are however limited since inadequate expansion of those cells or an 
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inappropriate response to high glucose levels result in β cell failure at later stages. Altogether, 
decreased mass and function of β cells in combination with insulin resistance are key factors to 
promote severe glucose intolerance leading to elevated fasting glucose plasma levels 
characterizing  type-2 diabetes mellitus15. 
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4.2. Mechanisms of insulin resistance 
 
 Peripheral insulin resistance is defined as a state when insulin action is blunted15. Insulin 
is the dominant hormone regulating plasma glucose level. Generally, insulin promotes glucose 
uptake mainly in skeletal muscle, liver and adipose tissue. Moreover, it promotes storage and 
synthesis of lipids, proteins and carbohydrates and inhibits their breakdown23. In the different 
cell types and organs, insulin regulates specific processes. In liver, it promotes glycogen 
synthesis and inhibits gluconeogenesis. In adipose tissue, it has been demonstrated to suppress 
lypolysis and the release of free fatty acids to the circulation24. In the central nervous system, 
insulin receptors have been shown to be widely expressed. Several actions of insulin in the 
brain have been reported as well. Insulin suppresses appetite and counteracts CNS-mediated 
hepatic glucose production16. 
 At the molecular level, binding of insulin to its receptor evokes a cascade of several 
molecular events including translocation of the glucose transporter 4 (Glut-4) from cell interior 
to the plasma membrane to allow glucose uptake, phosphorylation of glycogen-synthase kinase-
3 (GSK3) to promote glycogen formation25, inhibitory phosphorylation of FOXO-1 and/or 
FOXA2 to inhibit gluconeogenesis and/or β oxidation of FFA26-29, activation of mammalian 
target of rapamycin (mTOR) to promote protein synthesis and various molecular events 
promoting lipogenesis and preventing lipid break-down13. 
 The first event leading to cellular effects upon insulin binding to the insulin receptor (IR) 
is its conformational change and its autophosphorylation on multiple tyrosine residues  
including tyrosine 960 generating a recognition motive for the phosphotyrosine-binding domain 
(PTB domain) of insulin receptor substrates (IRSs)23, 30. The function of the IR in regulation of 
glucose homeostasis was studied extensively. Mice with a liver-specific deletion of the insulin 
receptor (LIRKO mice) exhibit dramatic insulin resistance and glucose intolerance leading to 
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progressive hepatic dysfunction31. Very recently, LIRKO mice have been shown to produce 
dyslipidemia and susceptibility to atherosclerosis32. Surprisingly, deletion of the insulin 
receptor specifically in skeletal muscles (MIRKO mice) did not alter blood glucose levels33. In 
contrast, deletion of the insulin receptor in adipose tissue (FIRKO mice)  resulted in a reduced 
fat pad mass, reduced triglyceride body content, decreased body mass and protection against 
obesity and glucose intolerance34. Furthermore, FIRKO mice show prolonged longevity35. 
Taken together, these data suggest a complex tissue-dependent function of insulin receptor 
signaling. 
 At least 12 substrates for the insulin receptor have been identified so far. The most 
characterized are IRS-1 and IRS-214. Deletion of IRS-1 in mice results in growth defects, severe 
insulin resistance and glucose intolerance36. Similarly, targeted disruption of IRS-2 results in 
development of diabetes37. 
 Upon phosphorylation on tyrosine residues, IRSs can interact with the regulatory subunits 
p85, p55 and p50 of the phosphoinosytol 3-kinase (PI3K). These regulatory subunits in turn 
bind to the catalytic subunits (p110) of PI3K which in turn converts  phosphatidylinositol 4,5-
diphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3)23. Activation of PI3-
kinase seems to be crucial for the translocation of Glut-4 to the plasma membrane since its 
blockage with specific inhibitor wortmannin markedly attenuates this process38. Mice with 
deletion of the p85α regulatory subunit of PI3K  show increased glucose tolerance and 
hypoglycemia since ablation of p85α leads to an overall increased PI3K activity39. Conversely, 
deletion of the catalytic subunit results in insulin resistance40. 
 PIP3 generation results in the activation of multiple downstream targets including 
phosphoinositide-dependent kinase 1 and 2 (PDK1 and 2) and subsequent activation of AKT 
isoforms 1 to 3 (also known as protein kinase B, PKB) and protein kinase C (PKC) ζ. 
Interestingly, PDK2 has been recently discovered to be the rapamycin-insensitive mTOR-Rictor 
complex41. Activated AKT in turn phosphorylates several targets including the AKT substrate 
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of 160kDA (AS160), the latter of which mediates GLUT4 translocation and regulates GSK3β 
and FOXO1 to control glucose homeostasis13, 23, 30. 
 In general, impaired insulin signaling leads to insulin resistance characterized by an 
impaired response to insulin in peripheral organs such as in liver, skeletal muscle and adipose 
tissue. Several molecular mechanisms accounting for attenuation of insulin action have been 
proposed. In early nineties, studies from Bruce Spiegelman’s and Gökhan Hotamisligil’s 
laboratories showed that tumor necrosis factor α (TNFα) is secreted in higher amounts from the 
adipose tissue of obese animals. Moreover, these studies showed that neutralization of TNFα 
increased insulin sensitivity and improved glucose tolerance42. Since this initial study 
implicating inflammation in obesity-related type-2 diabetes, multiple other lines of evidence 
have arisen to support this concept. First of all, increased TNFα abundance in the tissues 
derived from obese humans was shown43. Moreover, other inflammatory mediators such as 
interleukin-6 (IL-6) and monocyte chemoatractant protein-1 (MCP-1) have been demonstrated 
to mediate insulin resistance in obese mice20. 
 As mentioned above, adipocytes secrete adipokines such as leptin, visfatin, resistin and 
adiponectin, which regulate different aspects of metabolism and expression of multiple 
inflammatory mediators44. Adiponectin has been shown to generally promote insulin sensitivity 
and mediate anti-inflammatory effects44. Leptin is a master regulator of appetite. Mice deficient 
either in leptin (ob/ob mice) or leptin receptor (db/db mice) displays markedly increased food 
intake and severe obesity. In fact, mice carrying those mutations are widely used as animal 
models for studying the development of obesity and associated disorders45. Moreover, leptin is 
a potent regulator of proinflammatory mediators, promoting TNFα, IL-6 and IL-12 expression 
as well as neutrophil chemotaxis and T effector cells differentiation45. The recently discovered 
adipokine resistin has been shown to promote expression of TNFα and IL-6 and can be 
classified as insulin desensitizing factor46. In contrast, visfatin, an other newly identified 
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adipokine, promotes insulin sensitivity by direct interaction with the insulin receptor44. 
Deregulation of the secretion of adipokines, especially a decrease in secretion of adipokines 
promoting insulin sensitivity and an increase in secretion of insulin desensitizing factors during 
obesity, contributes to development of insulin resistance44-46. 
 Several recent studies suggest that obesity is associated with an increase of pro-
inflammatory macrophages migrating to the adipose tissue, which in concert with 
metabolically-overloaded adipocytes contribute to a low-grade inflammation47-49. 
 As a consequence of reduced insulin signaling, glucose uptake is decreased and insulin-
mediated suppression of lipolysis is attenuated. Additionally, dysfunctional adipocytes exhibit a 
reduced rate of triacylglycerol synthesis and accelerated lipolysis50, both of which are resulting 
in increased cellular efflux of free fatty acids (FFA). Increased lipotoxic FFA and systemic 
inflammation in turn may affect insulin sensitivity and lipid metabolism in liver and skeletal 
muscle leading to systemic insulin resistance and dyslipidemia and finally also might contribute 
to β cell dysfunction (see next chapter), all of which are pivotal to the development of type-2 
diabetes and associated disorders including atherosclerosis51 52. 
 Taken together, several studies confirmed that a low-grade chronic and systemic 
inflammatory state in the adipose tissue, dysbalanced adipokine secretion, as well as enhanced 
FFA release from adipocytes are key features in obese subjects mechanistically connecting 
adipose accretion with insulin resistance, dyslipidemia and finally impaired β cell function. 
However, the question remains how these factors suppress insulin action at the 
molecular level. For quite a while, it is fairly established that infectious agents and other 
environmental and cellular stresses trigger a number of metabolic responses. In fact, an acute 
infection leads to acute insulin resistance to elevate blood glucose levels, which is necessary to 
provide sufficient energy to immune cells, which are mainly dependent on glycolysis as a 
source to generate ATPP53, 54. Furthermore, acute infections lead to a plethora of physiologic 
alterations in lipid metabolism55-57. However, if inflammation and other stresses are sustained, 
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as for example in obesity, these responses can become detrimental and lead to life-threatening 
diseases such as cancer, diabetes and atherosclerosis. Among others, two main canonical 
pathways mediate the cellular responses to inflammation and other stresses, the Mitogen-
activated protein kinase (MAPK) and the nuclear factor kappa B (NFκB) pathway. These 
pathways appear to be chronically and highly activated in metabolically overloaded tissues4, 58. 
Moreover, several studies in knockout mice provide evidence that these signaling cascades are 
required to promote obesity-related insulin resistance. It was demonstrated that the MAPK 
JNK1, but not JNK2, promotes obesity and insulin resistance4. However, very recent data from 
the same research group provide evidence that also JNK2 is involved in metabolic regulation, 
but its function is compensated by JNK159. At the molecular level, JNK directly suppresses 
insulin signaling through a phosphorylation-induced inactivation of the insulin receptor 
substrate 1 (IRS-1) at Ser30760. JNK1 has been also shown to trigger inflammation in adipose 
macrophages to promote obesity-related insulin resistance5. Stress-induced JNK activation also 
occurs in macrophages residing in the vascular wall, which enhances their capacity to take up 
modified lipoproteins and thus promotes foam cell formation, a key process in atherogenesis, 
the latter of which is frequently associated with obesity and type-2 diabetes 61. 
 The nuclear factor kappa B (NFκB) signaling cascade represents another canonical 
pathway activated by stress and inflammatory agents62. Activation of most forms of NFκB, 
especially the most common form - the p50–RelA dimer - depends on phosphorylation-induced 
ubiquitination of the IκB proteins, the latter keeping NFκB in its inactive state. This sequential 
modification depends on two protein complexes: the IκB kinase (IKK) complex and the E3IκB 
ubiquitin ligase complex63. Once poly-ubiquitinated, the IκBs undergo rapid degradation 
through the 26S proteasome and the liberated NFκB dimers translocate to the nucleus, where 
they participate in transcriptional activation of specific target genes. IKK is composed of at 
least three subunits: the catalytic subunits IKKα and IKKβ, and the regulatory subunit, IKKγ. 
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The IKKα and IKKβ subunits preferentially form heterodimers, and both can directly 
phosphorylate the critical S32 and S36 residues of IκB. IKKγ serves a structural and regulatory 
purpose and is thought to mediate interactions with upstream activators of IKK in response to 
cellular activation signals64. 
 Importantly, IKKβ seems to promote obesity-related insulin resistance. In fact, heterozygous 
deletion of IKKβ protected against the development of insulin resistance during high fat 
feeding and in obese leptin deficient mice58. Consistently, it has been demonstrated that mice 
with macrophage-specific deletion of IKKβ retained insulin sensitivity in peripheral organs and 
were protected against insulin resistance in response to high fat diet and genetically-induced 
obesity. Moreover, liver-specific expression of a constitutive active form of IKKβ led to a 
subacute chronic inflammatory response in this organ and to the development of type-2 
diabetes in mice58. Deletion of IKKβ in insulin-responsive tissues had further illustrated its role 
in metabolism. Although hepatocyte-specfic deletion of IKKβ in mice does not affect liver 
insulin responsiveness, it results in insulin resistance in muscles and fat65. Muscle-specific 
inactivation of IKKβ does not affect insulin sensitivity in mice66. Deletion of other component 
of the NFκB signaling IKKγ specifically in liver results in protection from obesity-induced 
development of insulin resistance67. Taken together, these results suggest that activation of 
NFκB promotes insulin resistance although direct interaction with the insulin signaling cascade 
was not reported. It seems that activation of NFκB promotes inflammatory cytokine expression 
and indirectly attenuates insulin signaling. 
 These stress-induced kinases also mediate innate immune responses via signaling 
cascades induced by the Toll-like receptors (TLRs). Pathogen-associated molecular pattern 
(PAMP) recognition by Toll-like receptors (TLRs) constitutes a central mechanism for 
initiation of innate immune responses and the induction of pro-inflammatory cytokines and type 
I interferons during infection68. Intriguingly, it has been shown that FFA bind the toll-like 
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receptor TRL469, 70. As FFA are frequently elevetated in sera of obese subjects, binding of FFA 
on TLR4 might promote obesity-related inflammation71. Indeed,  deletion of TLR4 resulted in 
protection against obesity-induced insulin resistance56, 71, 72. Therefore, these data might explain 
how altered lipid metabolism is converted into a inflammatory stress program in adipocytes. 
Another upstream mechanism activating JNK and IKK in metabolically-overloaded tissues is 
the induction of endoplasmic reticulum stress (ER-stress)54. Mice with heterozygous deletion of 
the X-box binding protein 1 (XBP-1), a transcription factor which enhances transcription of ER 
chaperones and thus attenuates ER-stress, develop insulin resistance73. In contrast, in vivo 
delivery of chemical chaperones attenuates ER-stress in obese animals, thereby improving 
insulin sensitivity74. 
 In conclusion, the following simplified and adipocentric model of obesity-related insulin 
resistance can be proposed: Enhanced nutrient intake and reduced energy expenditure leads to 
storage of fat in adipocytes. Metabolically-overloaded adipocytes aberrantly induce 
inflammatory pathways, secrete higher amounts of insulin-desentizing adipokines (i.e. resistin), 
decreased amounts of insulin-sensitizing adipokines (i.e. adiponection and visfatin) and release 
markedly more FFA mainly by increasing lipolysis. These factors might impair the metabolic 
function of other organs such as liver and skeletal muscle leading to systemic insulin resistance 
(Fig. 1). 
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Fig. 1 Development of insulin resistance.  Positive energy balance, caused by increase food intake and reduced 
energy expenditure, results in increase adiposity and obesity. Metabolically overloaded adipocytes secretes 
increase amount of insulin-desensitizing and reduced amount of insulin-sensitizing adipokines. Moreover, increase 
adiposity leads to the induction of inflammatory pathways and increase lipolytic activity. Increase levels of the 
inflammatory mediators (IL-6, TNFa), FFAs and insulin-desensitizing hormones results in the systemic insulin 
resistance.        
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4.3. Pancreatic β cell function 
 
 Insulin is secreted from pancreatic β cells in response to glucose. Several factors 
amplifying glucose-stimulated insulin secretion have been identified including insulinotropic 
gut peptides such as glucagon like peptide 1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP)75, β-adrenergic stimulation1 and neurotransmitters such as acetylcholine76. 
 Secretion of insulin is regulated by a number of subsequent steps. Glucose enters 
pancreatic β-cells through the high affinity glucose transporter 2 (Glut-2). Glucose is 
metabolized through glycolysis followed by oxidative metabolism of glucose in the 
mitochondria leading to the production of ATP. As a consequence, the  ATP/ADP ratio 
increases resulting in closure of ATP-dependent potassium channels and depolarization of the 
plasma membrane. This causes opening of voltage-gated calcium channels and extracellular 
calcium influx into the cell interior and finally leads to insulin granule exocytosis1. In fact, 
insulin granules within the cell undergo extensive movement. Insulin granules in β cells exist 
in two pools; vesicles which are morphologically docked to the plasma membrane, also 
termed the rapidly releasable pool, which accounts for approximately 10 % of the total 
cellular insulin content and vesicles located more far away from the plasma membrane, the so 
called intracellular reserve pool. The first phase of insulin secretion is mainly triggered by the 
rapidly releasable pool. In order to allow efficient insulin exocytosis during the second phase 
of insulin secretion, insulin granules from the reserve pool are transported to the proximity of 
the plasma membrane in a cytoskeleton-mediated, ATP-dependent manner77. 
 As already mentioned above, insulin secretion is regulated also by insulinotropic agents; 
GLP-1 or β-adrenergic stimulation leads to an increase of cyclic AMP levels, which activates 
protein kinase A (PKA) and the guanine nucleotide exchange factor (EPAC2) and stimulating 
the closure of ATP-dependent potassium channels and release of intracellular calcium stores1, 
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75. Acetylcholine released from parasympathetic synapses act through the muscarinic 
receptors and stimulate intracellular diacylglycerol (DAG) production, which also releases 
calcium from intracellular stores and promotes insulin granule secretion78, 79. 
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4.4. Pancreatic β cell function in type-2 diabetes 
  
 During the state of insulin resistance, an increased amount of insulin is required for 
maintaining normal glucose levels. In general, full-blown type-2 diabetes occurs when the 
amount of insulin does not meet the metabolic demand and fasting glucose are above the 
normal values15.  
 Hyperinsulinemia during the early phase of insulin resistance results from an increase in 
pancreatic β cell mass and from enhanced capacity of cells to secrete insulin. Pancreatic β 
cells expansion has been observed in insulin resistant, obese rats, mice as well as humans80-82. 
β cell expansion is caused by proliferation of existing β cells and/or neogenesis from 
pancreatic ductal cells83. It is not entirely clear what the relative contribution of these two 
processes is to compensate insulin resistance. However recent studies seem to confirm the 
presence of multipotent progenitor cells in pancreas from adult mice which can differentiate 
into functional β cells84. 
 Several factors, which are increased in the serum of the insulin-resistant individuals, 
have been proposed to stimulate pancreatic β cell expansion. Especially increased levels of 
nutrients such as glucose and free fatty acids (FFA) can promote proliferation of pancreatic β 
cells85, 86. Moreover, multiple hormones including GLP-1, GIP, hepatocyte growth factor 
(HGF), insulin-like growth factor 1 (IGF-1) and insulin itself have been shown to stimulate 
pancreatic β cell proliferation75, 87-89. GLP-1 has been shown to promote pancreatic β cell 
proliferation, neogenesis and survival75, 89. Treatment of diabetic individuals with GLP-1 
analogues ameliorates hyperglycemia and increases pancreatic β cell mass67. At the molecular 
level, signaling from GLP-1 receptor (GLP-1R) activates multiple signaling cascades 
including mitogen activated protein kinase (MAPK), PI3-kinase, and protein kinase A (PKA) 
and leads to activation of a transcriptional response including activation of pancreatic and 
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duodenal homeobox factor-1 (PDX-1), a crucial regulator of differentiation and function of 
pancreatic β cell52. In fact, effects of GLP-1 was shown to be completely abolished in the 
absence of PDX-190.  Another closely related incretin hormone, GIP, has been shown to 
promote similar effects on β cells, however the molecular mechanisms of GIP action are less 
understood52, 67. Interestingly, signaling mediated by insulin and IGF-1 has been shown to be 
crucial for maintaining an appropriate mass of pancreatic β cells in the body.  Pancreatic β 
cell specific deletion of the insulin receptor in mice led to a reduced insulin content in the 
pancreas due to decreased pastnatal β cell growth and resulted in the development of 
diabetes91, 92. Consistently, IRS-2 has been shown to be crucial for β cell development and to 
compensate for peripheral insulin resistance, since IRS-2 knockout mice displayed loss of 
pancreatic β cells associated with decreased insulin secretion and glucose intolerance93. In 
contrast, IRS-1 rather seems to be important in mediating peripheral insulin action93. IRS-1 
knockout mice display primarily severe insulin resistance but show pancreatic β cell 
hyperplasia to counteract insulin resistance94. Mice with deletion of the IGF-1 receptor in 
pancreatic β cells show decreased β cell mass and inappropriate development of pancreatic 
islets93. 
 As mentioned above, pancreatic β cells can compensate peripheral insulin resistance not 
only through expansion of their mass, but also by increasing the capacity of the existing β 
cells to secrete insulin. In fact, several factors which were shown to promote pancreatic β cell 
expansion are also implicated in stimulation of insulin secretion. Increased pancreatic β cell 
glucose metabolism, stimulation with FFA, increased signaling by incretin hormones and 
parasympathetic nervous stimulation are the main factors accounting for the stimulation of β 
cell function during the state of insulin resistance83. Enhanced glucose metabolism is coupled 
to increased expression of the rate limiting factors involved in this process. Increased glucose 
entry into the pancreatic β cells is mediated by the glucose transporter GLUT-2, which was 
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shown to be more abundant on the surface of β cells from insulin resistant subjects83. 
Similarly, enhanced entry of glucose into the Krebs cycle in mitochondria is coupled to 
increased activity of glucokinase, the rate limiting enzyme in cytosolic glycolysis83. 
Stimulation of insulin secretion by FFAs, the levels of which are markedly increased in the 
state of obesity and peripheral insulin resistance, is mediated by G protein-coupled receptor 
40 (GPR40). Signaling from this receptor leads to increased intracellular Ca2+ content and 
stimulates insulin granule exocytosis95, 96. Also the incretin hormone GLP-1 has been shown 
to promote pleiotropic effects on β cell function. Enhanced signaling from the GLP-1 receptor 
leads to the stimulation of insulin biosynthesis, promotes the release of intracellular Ca2+ 
stores and evokes depolarization of the cell membrane by promoting closure of the ATP-
dependent potassium channel1, 75, 97. Several lines of evidence implicated the autonomic 
nervous system in the regulation of insulin secretion. In general, parasympathetic neurons 
stimulate and sympathetic neurons suppress insulin secretion98. Recent results indicated that 
parasympathetic neurons might contribute to enhanced insulin secretion in the state of insulin 
resistance since overexpression of the muscarinic M3 receptor (receptor for acetylcholine, one 
of the main neurotransmitter of the parasympathetic neurons) specifically in the pancreatic β 
cells leads to increased insulin release, improved glucose tolerance and protects mice from 
diet-induced glucose intolerance and hyperglycemia. Conversely, deletion of muscarinic M3 
receptor specifically in β cells results in impaired insulin release and glucose intolerance79. 
 Although pancreatic β cells initially can compensate for an increased insulin demand 
caused by peripheral insulin resistance, several initial compensatory mechanisms in the long 
term lead to β cell failure15, 83 (Fig. 2). Among others, chronic exposure of pancreatic β cells 
to high glucose and high levels of FFA, resulting in so called gluco- and lipotoxicity, are most 
prominent factors contributing to the β cell failure99, 100. Gluco-  and lipotoxicity is manifested 
by a decreased pancreatic β cell function caused by a reduction in insulin transcription and 
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translation, decreased expression of proteins involved in regulation of glucose-stimulated 
insulin secretion such as GLUT-2 and voltage-gated  Ca2+ channel. Moreover, chronic 
exposure to both glucose and FFA results in the induction of ER- and oxidative stress, which 
might in turn lead to apoptosis99-101. Along this line, exposure of β cells with high glucose 
results in activation of sterol regulatory element binding protein-1c (SREBP-1c) and 
subsequent induction of lipogenic pathways, which results in the accumulation of lipids in β 
cells and induction of ER-stress90. In addition to the induction of ER-stress by deposition of 
lipids in β cells, FFA mediated signaling through the β cell-specific receptor GPR40 also 
contributes to β cell failure during development of diabetes, since overexpression of this 
receptor in β cells leads to failure of these cells and the development of diabetes96. 
Hyperglycemia has been also implicated in the stimulation of mitochondrial superoxide 
production and induction of oxidative stress102. Oxidative stress contributes to β cell failure 
by several mechanisms including induction of apoptosis100 and by decreasing the production 
of ATP through activation of uncoupling protein 2 (UCP2), leading to decreased insulin 
exocytosis103. Another possible mechanism mediating the loss of β cell mass is deposition of 
islet amyloid in β cells. Formation of amyloid deposits results from aggregation of islet 
amyloid polypeptide (IAPP). IAPP is secreted from β cells together with insulin; moreover 
secretion of these proteins seems to be co-regulated104. Interestingly, IAPP aggregation does 
not occur in rodents due to differences in the amino acid sequence between human and rodent 
IAPP. In fact, the only genetic evidence highlighting the importance of pancreatic β cell 
amyloid deposition in type-2 diabetes stems from experiments in which ectopic expression of 
the human IAPP specifically in mouse pancreatic β cells has been achieved. Overexpression 
of human IAPP in wild-type mice did not result in alterations of β cell function and deposition 
of amyloid aggregates. However, in the insulin resistant ob/ob mouse strain ectopic 
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expression of human IAPP resulted in severe amyloid deposition, loss of β cells and severely 
increased hyperglycemia105. 
 Apart from above described mechanisms, a number of monogenic mutations leading to 
β cell failure and diabetes have been described. The most characterized are a group of 
mutations collectively called maturity onset diabetes of the young (MODY). MODY 
mutations cause approximately 2-5% of all cases of diabetes. Six different subtypes of 
MODY mutations are classified, based on the affected locus that has been identified (MODY1 
– MODY6)106. The most common form, MODY2 results from the mutation in the gene 
encoding glucokinase: the enzyme responsible for the initial step of glycolysis. MODY2 
mutations result in defective glucose sensing in pancreatic β cell and increases the threshold 
of glucose concentration required for initiation of insulin secretion107. MODY3 results from 
the mutations in hepatocyte nuclear factor 1α (HNF1α); usually subjects with mutations in 
this gene develop severe diabetes caused by insufficient insulin secretion108. Other mutations 
in the transcription factors hepatocyte nuclear factor 4α (HNF4α) and hepatocyte nuclear 
factor 1β (HNF1β) have been identified as MODY1 and MODY5, respectively109, 110. 
Mutations in the key transcription factor PDX-1, involved in differentiation and maintenance 
of pancreatic β cell function, has been described as MODY4111. MODY6 results from 
mutations in NeuroD1/β2 and leads to the development of severe diabetes112. 
 In conclusion, pancreatic β cell failure strongly contributes to the development of type-2 
diabetes mellitus. As for many other compensatory mechanisms, factors and pathways 
initially enhancing the efficiency of β cells, in the same time may lead to induction of 
maladaptive processes accounting for β cell failure when they are chronic in nature (Fig. 3).                            
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Fig. 2 Development of type-2 diabetes. Increased adiposity in obese subjects leads to increased circulating 
adipokines, FFAs and inflammatory mediators resulting in peripheral insulin resistance. Increased demands of 
insulin caused by insulin resistance is initially compensated by pancreatic β cells through different mechanisms, 
which initially prevents development of full-blown type-2 diabetes mellitus. However, prolonged exposure of 
cells to these factors, which are also key in inducing insulin resistance, lead to pancreatic β cell failure and 
results in type-2 diabetes mellitus (adapted from 15). 
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4.5. The Mitogen-Activated Protein Kinase (MAPK) signaling cascade 
 
 A number of stress-induced signaling pathways including MAPKs have been shown to 
be implicated in the development of insulin resistance, pancreatic β cell dysfunction and as 
consequence in the development of type-2 diabetes4-8, 19, 20, 58, 65, 67. 
 In mammals, four conventional and three atypical MAPK families exist. The 
conventional MAPK are comprised by the extracellular regulated kinase 1 and 2 (ERK1,2), c-
jun N-terminal kinase (JNK), p38 and the extracellular regulated kinase 5 (ERK5). The 
atypical MAPKs consist of  the extracellular regulated kinase 3 and 4 (ERK3,4), the 
extracellular regulated kinase 7 and 8 (ERK7,8) and the NEMO-like kinase (NLK) 113-115. 
Within the kinase domain, all the members of the MAPK branch display more than 40% of 
amino acid sequence identity compared to ERK1115. 
 Conventional MAPKs are activated by a largely defined upstream protein kinase 
cascade. In general, upon stimulation with multiple agents such as growth factors, cytokines 
and stress, G-protein coupled receptors activate MAPK kinase kinases (MAPKKKs), which 
target downstream MAPK kinases (MAPKKs) leading to subsequent activation of MAPKs113. 
Another characteristic feature of the conventional MAPK is the presence of the Thr-X-Tyr 
motif in the activation loop, which is the site of activation by MAPKK60. The activation of 
atypical MAPKs is generally not mediated by MAPKKs, although the exact mechanisms of 
activation of these kinases are still not well understood115. 
 Through phosphorylation of downstream targets, MAPK regulates a whole plethora of 
basic cellular processes including proliferation, differentiation, apoptosis, migration and 
inflammation60, 113, 116 (Fig. 3). 
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 Fig. 3 Stress-activated MAPK signaling modules. MAPK regulates most of the basic cellular processes. 
MAPK are comprised of a three-tier kinase module, in which a MAPK is activated upon phosphorylation by 
MAPKK, which in turn is activated when phosphorylated by MAPKKK (adapted from113). 
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4.6. The MAPK family JNK 
 
The JNK proteins are encoded by three genes: JNK1, JNK2 and JNK3. While JNK1 
and JNK2 are expressed ubiquitously, JNK3 has a limited pattern of expression and is largely 
restricted to brain, heart, and testis117. Numerous studies in animal models established a key 
role of JNK in various pathological conditions including cancer, cardiac hypertrophy/failure, 
neurodegenerative disorders, arthritis and asthma. Lately, it has been demonstrated that JNK1 
but not JNK2 promotes obesity and insulin resistance4. However, very recent data from the 
same research group provide evidence that JNK2 is also involved in metabolic regulation, but 
its function is compensated by JNK159. At the molecular level, JNK directly suppresses 
insulin signaling through a phosphorylation-induced inactivation of the insulin receptor 
substrate 1 (IRS-1) at Ser30760. Activation of JNK and other inflammatory and/or stress-
induced kinases including inhibitor of nuclear factor-κB (IKK) most likely occurs through 
metabolic overload-mediated induction of ER stress54. ER stress-mediated activation of these 
kinases leads to an enhanced inflammatory response since the very same kinases are key 
mediators of transcription and secretion of numerous cytokines. The activity of these kinases 
is further enhanced in response to elevated cytokines and hence exacerbates insulin resistance. 
For example, TNFα, a pivotal pro-inflammatory cytokine, is highly expressed in adipose 
tissue of obese and insulin resistant animals and humans42, 118. Concordantly, obese mice 
lacking either TNF-α or TNF-α receptors are protected against insulin resistance4. Recent 
studies also support that increased activity of JNK attenuates insulin production and secretion 
as well as increases apoptosis in the pancreatic islets119-125. 
ER stress induction and subsequent activation of JNK also occurs in cholesterol-overloaded 
macrophages in the atherosclerotic lesion90. In our own previous study, we demonstrated 
pronounced activation of JNK in atherosclerotic lesions in mice. Moreover, we provided clear 
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in vivo evidence that JNK2 promotes atherosclerosis through a macrophage-specific 
mechanism61. 
These mechanisms are likely to occur not only in adipocytes and macrophages but also in 
other cell types including hepatocytes, skeletal muscle cells and β-cells rendering these 
kinases as very attractive drug targets in type-2 diabetes. Thus, ER stress and JNK activation 
represent key unifying mechanisms in the development of the various conditions within the 
metabolic syndrome. 
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4.7. The MAPK family p38 
 
 The closely related p38 signaling cascade likewise appears to mediate various molecular 
events in response to inflammatory, stress and metabolic stimuli. Four isoforms of p38 MAPK 
have been identified: p38α126, p38β 127, p38γ 128 and p38δ129. p38 isoforms share about 60% 
homology, the highest between the α  and β isoforms (74%). 
Activation of p38 occurs via dual phosphorylation of conserved TGY motifs by the 
MAPKKs, MKK6 and MKK3117. All the isoforms share two highly similar common docking 
domains predominantly responsible for the kinase substrate interaction. In contrast to other 
isoforms, p38γ contains a PDZ binding motif at the C-terminal end, allowing interaction with 
PDZ domains of other proteins. Despite the high similarity between the four isoforms, the N- 
and C-terminal sequences of the amino acids display a high variability and might determine 
specific functions of these proteins. 
In contrast to JNK, very little is known about the role of p38 in vivo and the contribution of 
different p38 isoforms to several biological processes is poorly understood, and in some 
instances even controversial. This is mainly due to the fact that isoform-specific inhibitors start 
to be available only now. In addition, conventional knockout, as well as conditional knockout 
mice have been generated only very recently and the analyses of these animals have just started. 
 p38 has been mainly implicated in the regulation of innate immunity. Several studies have 
suggested an involvement of p38 in the production of inflammatory factors such as TNFα, IL-
1126, 130, 131, IL-6132, IFN-γ133, 134 and IL-12134, 135, but also the anti-inflammatory factor IL-10134, 
136, 137. Expression studies revealed that p38 might be involved in inflammatory diseases such as 
rheumatoid arthritis138, Alzheimer’s disease53, inflammatory bowel disease139 and acute 
respiratory distress syndrome140. 
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Fig. 3 Alignment of p38 isoforms. Sequence alignment of different p38 isoforms revealed their high homology 
(around 60%). The lowest similarity is observed at the ends of the sequence. All the isoforms share the dual 
phosphorylation activatory motif (blue frame) and the common docking domain (yellow frame). The PDZ domain 
binding motif is unique to the p38γ isoform (violet frame). In the right panel, the homology tree of p38 isoforms is 
indicated
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 However, the role of p38 is not confined to cytokine production. Several experiments 
support the idea that p38 might play a central role in cellular metabolic processes. With respect 
to adipocytes and muscle, p38 has been reported to be activated in insulin-resistant peripheral 
tissues from diabetes patients141. Insulin-stimulated activation of p38 has been observed in rat 
skeletal muscles142, mouse brown adipocytes143, murine 3T3-L1 adipocytes144-146 and L6 
muscle cells147, 148. However, an involvement of p38 in glucose uptake through direct action on 
GLUT4, the main glucose transporter in muscle cells and adipocytes, remains highly 
controversial at this point149-151. Nevertheless, central metabolic regulators such as the 
transcription factor CREB152, 153 and the transcriptional cofactor PGC-1α154 are targets of 
p38 implicating a role of this kinase family in thermogenesis, gluconeogenesis and lipid 
metabolism154-158. The transcriptional coactivator PGC-1α coordinates expression of genes 
including UCP-1 stimulating mitochondrial oxidative metabolism29. p38 also directly stimulates 
expression of the UCP-1 gene through phosphorylation of the transcription factor ATF-273. 
Moreover, p38 might be implicated in regulation of insulin production and pancreatic β-cell 
biology159, 160. 
 Finally, data in vitro have demonstrated that p38 activation upon insulin, TNFα, free fatty 
acids and other stress stimuli impairs insulin signaling in adipocytes and skeletal muscle cells 
through very similar mechanisms as described above for JNK161. Furthermore, there is also 
experimental evidence in vitro that p38 might promote adipogenesis40. 
 With respect to the cardiovascular part of the metabolic syndrome, several independent 
studies imply that p38 also partially regulates initial events in atherosclerosis such as 
endothelial cell activation, leukocyte adhesion/migration and foam cell formation162-171. 
Accumulation of free cholesterol is known to occur in macrophages at later stages of 
atherosclerosis and is associated with ER stress and increased apoptosis leading to secondary 
tissue necrosis and destabilization of the atherosclerotic plaque. Indeed, p38 in cooperation with 
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JNK seems to convert ER stress into the expression of cytokines in macrophages65. On the 
other hand, novel data support the idea that p38 cooperates with the NF-κB pathway to mediate 
macrophage apoptosis155 (Fig. 4). 
 
 
 
 
 
Fig. 4 An overview of possible functions of p38 isoforms in different metabolic processes. Multiple in vitro 
and expression/activation studies reveled possible functions of p38 in metabolism and functions of different cell 
types and organs (for details: see text). 
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 However, the requirement of p38 in vivo in most of the processes mentioned above, as 
well as the specific roles of p38 isoforms are largely unknown. This is mainly due the fact that 
most of the available data about p38 and its role in different biological processes were 
obtained by using pyridynyl imidazole-based p38 inhibitors, which target p38α and p38β, but 
not p38γ and p38δ172-175. 
 Only recently, investigators start to use isoform-specific approaches (knockout mice) 
highlighting that different isoforms of p38 indeed possess different functions. 
 The best characterized p38 isoform is p38α. It has been shown that p38α knockout mice 
die at midgestation, likely due to a defective erythropoiesis29. However, another research team, 
using tetraploid blastocyst injection approach, demonstrated that p38α is required for placental 
organogenesis suggesting that all other observed developmental defects are most likely 
secondary176. Recently another group using conditional p38α knockout mice showed that p38α 
is not required for erythropoiesis since deletion of p38α in the embryo, but not in the 
extraembryonic tissue, using the More-Cre deleter strain, does not result in embryonic 
mortality, but results in postnatal mortality due to severe lung dysfunction177. One of the first 
sets of data concerning the function of the p38α in adult mice using a conditional approach has 
been obtained only very recently. p38α seems to play a critical role in cardiomyocyte survival 
and proliferation but not in cardiac hypertrophic growth178, 179. Other recent reports suggested 
that p38α is a fundamental regulator of proliferation and carcinogenesis in vivo177, 180-182 (Fig. 
6). 
 p38α shares more than 70% amino acid sequence identity with p38β. Thus, inhibitors 
and/or deletion strategies used in most studies described above targeted both p38α and 
p38β isoforms. Nevertheless, it was assumed that p38α and p38β cooperate in inflammatory 
and metabolic processes. This assumption was lately contradicted, since it has been 
demonstrated that p38β-specific knockout mice showed no differences in several in vivo and in 
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vitro models of inflammation 151. Furthermore, another recent study does not support a direct 
link between p38β and insulin signaling 151. However, another group showed that p38β might 
be involved in regulation of cardiomyocyte hypertrophy 183, suggesting specific functions of 
this isoform. 
 The least characterized isoforms are p38γ and p38δ. p38γ shares 60% homology to p38α. 
So far in vitro data suggests that this isoform might be involved to regulate the osmotic stress 
program 184 and regulates glucose uptake in skeletal muscles185 (Fig. 5). 
 The fourth isoform of p38 MAPK kinase – p38δ, also known as SAPK4, has been cloned 
and partially characterized in 1997. p38δ shares significant homology with other p38 isoforms 
(60%) and about 40% of homology to other members of the MAPKs, JNK and ERK129 
 Recent in vitro studies have shown that p38δ might be involved in keratinocyte 
differentiation186-188 and PKCδ-dependent keratinocyte apoptosis188. p38δ could also be 
involved in the progression of neurodegenerative disorders, since it has been shown to 
phosphorylate Tau, a microtubule-associated protein that is abnormally hyperphosphorylated 
in the filamentous lesions that define a number of neurodegenerative diseases collectively 
referred to as tauopathies189, 190. Moreover, p38δ might mediate carcinogenesis by affecting 
survival, proliferation and invasion of the tumor cells191. Several other in vitro studies point 
out that p38δ might be important in the regulation of transcription, translation and activation 
of different proteins. p38δ has been shown to phosphorylate and deactivate eukariotic 
elongation factor 2 kinase (eEF2 kinase) leading to dephosphorylation and activation of 
eukariotic elongation factor 2 (eEF2)192. p38δ also seems to suppress MKK6-mediated AP-1 
activation through downregulation of c-jun and c-fos expression193. Furthermore, it appears to 
be required for transforming growth factor β 1 (TGFβ1)-stimulated vascular endothelial 
growth factor 164 (VEGF 164) transcription in murine mesengelian cells194 and last, but not 
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least suppresses LPS stimulated transcription of heme oxygenase 1 (HO-1)195 (Fig. 5). But no 
specific in vivo functions for p38δ have been reported thus far.  
 
 
 
Fig. 5 Functions of p38 isoforms. All four p38 isoforms have been shown to be activated by similar stimuli, 
however due to the structural differences, pyrydinyl imidazole-based inhibitors block the activity only of the two 
closest related isoforms α and β, but not γ and δ. Analyzes of the isoform-specific functions revealed several 
functional differences (for details: see text). 
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5. Aim of the project  
 
 Over the last decades, the prevalence of type-2 diabetes and associated disorders 
increased dramatically196. Multiple studies established the function of stress-activated 
signaling cascades including MAPKs in a number of pathological conditions including type II 
diabetes and associated disorders4, 19, 54, 61, 65, 197-202. 
 In particular, also the stress kinases p38 have been implicated in multiple pathological 
conditions including diseases related to metabolism. However, most of the conclusions were 
based on in vitro and expression studies. Moreover, specific functions of the p38 isoforms 
have not been identified so far. The aim of my project was to identify a specific in vivo 
function of the fourth p38 isoform, p38δ in particular in the context of metabolism. 
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6. Results  
 
 The p38 MAPK family consists of the four genes p38α (MAPK14), p38β (MAPK11), 
p38γ (MAPK12) and p38δ (MAPK13). p38α has been explored in a plethora of signalling 
cascades and in the context of several diseases9. In contrast, in vivo functions of the other p38 
isoforms are largely unknown. The isoform p38δ shares around 60% homology with the other 
p38 family members and about 40% homology with other MAPKs. Alike p38α, p38δ is 
activated by various stress stimuli, including inflammatory cytokines174. Recent in vitro 
studies have demonstrated that p38δ might be involved in keratinocyte differentiation187 and 
PKCδ-dependent keratinocyte apoptosis188, as well as the progression of neurodegenerative 
disorders referred to as tauopathies190 but no specific in vivo functions have been reported 
thus far. 
To address such functions, we have generated Mapk13 floxed mice and crossed them with 
mice expressing Cre recombinase under control of the Protamine promoter. The Protamine 
promoter-driven Cre recombinase efficiently recombines target sequences in the male germ 
line of mice203. With this approach, we obtained Mapk13 null mice (Mapk13Δ/Δ mice) and 
corresponding wild type control littermates (Mapk13+/+) (Fig. 6a, b and c). The Mapk13Δ/Δ 
mice did not show any apparent macro- and histopathologic abnormalities (data not shown). 
The highest expression of Mapk13 mRNA has been reported in mouse pancreas, testis, small 
intestine and prostate gland129. We now document that in the pancreas p38δ is abundantly 
expressed also at the protein level, and in similar amounts in the exocrine and endocrine parts. 
In contrast, no measurable expression of p38δ could be detected in the main insulin-sensitive 
organs, including adipose tissue, liver, and skeletal muscle (Fig. 7a and supplementary Fig. 
8a). 
 
 39
  
Figure 6 Generation of Mapk13 floxed mice and Mapk13Δ/Δ mice using Protamine-cre. (a) Schematic 
representation of the targeting strategy employed to generate a floxed allele of Mapk13. Exons 1 and 2 of the 
Mapk13 open reading frame are represented by rectangles, thin lines represent untranslated regions of the 
Mapk13 locus. The neomycin resistance gene (for positive selection) flanked by two FRT sites (FRT-neoPGK-
FRT) and the HSV-tk cassettes (for negative selection) are indicated. The arrows indicate the position of the 
primers for genotyping, loxP sites are shown as triangles. The strategy for generation of the targeted allele is 
described in Methods. (b) PCR analysis of genomic DNA isolated from adult Mapk13+/+, Mapk13f/+  and 
Mapk13f/f mice using D1, PGK-162r and BI5-12 primers, yielded a 744 bp band corresponding to the floxed 
allele and a 560 bp band corresponding to the wild type allele. (c) PCR analysis of genomic DNA isolated from 
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mice carrying deletion of Mapk13 by Protamine Cre; Mapk13Δ/Δ, Mapk13Δ/+ and Mapk13+/+. PCR was 
performed using D2 and BI5-12 and yielded a 799 bp band corresponding to the wild type allele and a 555 bp 
band corresponding to the deleted Mapk13 allele. 
 
 
 
Figure 7 Mice lacking Mapk13 show improved glucose tolerance and enhanced insulin secretion. (a) 
Western blotting revealed expression of p38δ in wild type (+/+) pancreas but not in liver, skeletal muscle 
(SKM), white (WAT) and brown adipose tissue (BAT) as well as tissues from Mapk13 null (Δ/Δ) mice. 
Coomassie blue was used to confirm equal loading. (b) Glucose tolerance of Mapk13 mice (squares and dashed 
line, n=10) was significantly improved (*p<0.05, **p<0.01) compared to that of wild type Mapk13+/+ littermates 
(diamonds and solid line, n=9). (c) Parallel measurements of serum insulin showed that, during the GTT test, 
Mapk13Δ/Δ mice (squares and dashed line, n=5 for each time point) had higher (*p<0.05) basal and stimulated 
levels of the circulating hormone than Mapk13+/+ mice (diamonds and solid line, n=5 for each time point). (d) In 
response to indicated stimuli (Glc: glucose, KCl: potassium chloride, tolb.: tolbutamide), insulin release was 
enhanced in isolated Mapk13Δ/Δ islets (black bars, n=15) compared to Mapk13+/+ islets (white bars, n=15) 
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(*p<0.05). (e) Glucagon secretion in in vitro cultured isolated  islets in response to 2.8 mM and 16.7 mM 
Glucose. Under both conditions no differences in islets isolated from Mapk13Δ/Δ (black bars, n=14) compared 
to Mapk13+/+ (white bars, n=16) could be observed. Glucagon secretion was normalized to glucagon content. 
 
 
 
Figure 8 Abundant expression of p38δ in pancreas and normal insulin sensitivity in Mapk13Δ/Δ mice. (a) 
Relative expression of Mapk13 mRNA, as tested by quantitative real time (RT)-PCR, showed expression of p38δ 
in isolated islets and total pancreas (Panc.) of Mapk13+/+ but not Mapk13Δ/Δ mice, and a low expression in 
skeletal muscle (SKM) but not in liver, white (WAT) and brown adipose tissue (BAT). Expression levels were 
normalized to those of 18S rRNA. (b) Insulin tolerance tests. Insulin (1 U/kg) was injected intraperitoneally in ad 
libitum fed mice and glucose was measured at indicated time points. Insulin sensitivity was equal in Mapk13Δ/Δ 
(squares and dotted line, n=5) and Mapk13+/+ (diamonds and solid line, n=6) mice. No signifcant differences  in 
insulin sensitivity between Mapk13Δ/Δ and Mapk13+/+ mice were observed. 
 
 This expression pattern prompted us to investigate the role of p38δ in pancreatic β 
cells and glucose homeostasis. For this purpose, we challenged mice with intraperitoneal 
glucose and monitored blood glucose levels over time (glucose tolerance test, GTT). 
Mapk13Δ/Δ mice fasted for 16 hours showed a significantly enhanced glucose tolerance 
compared to Mapk13+/+ mice (Fig. 8b), suggesting increased peripheral insulin sensitivity 
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and/or enhanced insulin release. In response to administration of insulin (insulin tolerance 
test, ITT), plasma glucose levels similarly declined in Mapk13Δ/Δ and Mapk13+/+ mice 
indicating normal insulin sensitivity (Fig. 8b). In contrast, Mapk13Δ/Δ mice displayed higher 
levels of circulating insulin than Mapk13+/+ control mice during the glucose tolerance test 
(Fig. 7c), suggesting enhanced insulin secretion. Accordingly, islets isolated from Mapk13Δ/Δ 
mice showed a higher basal as well as glucose-stimulated insulin release than islets of 
Mapk13+/+ littermates (Fig. 7d), while glucagon secretion was unaltered in Mapk13Δ/Δ 
compared to Mapk13+/+ mice (Fig. 7e) indicating that the insulin-secreting pancreatic β cells 
but not the glucagon-producing α cells in islets are affected. To confirm that lack of p38δ 
enhances insulin secretion in pancreatic β cells, we generated MIN6 cells (murine insulinoma 
cell line) stably expressing small hairpins (shRNA) against Mapk13, and control cells 
expressing an empty vector. Efficient knockdown of p38δ was confirmed by Western blotting 
(Fig. 9a). Compared to control cells, MIN6 cells lacking Mapk13 featured enhanced insulin 
secretion in the presence of basal (2.8 mM) but not of stimulatory glucose levels (25 mM), 
possibly because MIN6 cells are maximally stimulated at this glucose concentration (Fig. 9b). 
 
 
 
Figure 9 Stable expression of shRNA against Mapk13 in MIN6 cells enhances insulin secretion. (a) Western 
blot to determine endogenous expression of Mapk13 in MIN6 cells stably expressing a control vector and small 
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hairpin RNA (shRNA) against  Mapk13. Efficient deletion of  Mapk13 was achieved in shRNA-expressing cells. 
Tubulin was used as a loading control. (b) Insulin secretion of MIN6 cells stably expressing a shRNA against 
Mapk13 and control cells expressing the empty vector. Compared to control cells (white bars), cells depleted of 
Mapk13 (black bars) showed enhanced insulin secretion at basal (2.8 mM) but not at stimulatory glucose levels 
(25 mM) (*p<0.05 and ns, not significant, unpaired Student’s t test). 
 
 To assess whether enhanced kinase activity of p38δ in pancreatic β cells was sufficient 
to suppress insulin secretion, we generated INS1 cells (rat insulinoma cell line) stably 
expressing hemagglutinin (HA), HA-tagged wild type Mapk13 and HA-tagged constitutively 
active Mapk13. Constitutive p38δ activity was obtained by point mutations resulting in the 
substitution of aspartate 176 with alanin (D176A) and phenylalanine 324 with serine (F324S), 
as previously described204. We tested the activity of these mutants with an in vitro kinase 
assay using recombinant HIS-tagged ATF-2 as a substrate. Amino acid substitution F324S 
was more efficient at enhancing p38δ activity than substitution D176A (Fig. 10a) and was 
thus chosen for functional experiments. Stable expression of HA, HA-tagged wild type (HA- 
Mapk13wt) and mutated HA-tagged Mapk13 (HA- Mapk13F324S) was confirmed by Western 
blotting (Fig. 10b). INS1 cells stably expressing wt p38δ revealed a glucose-induced insulin 
secretion similar to that of control cells (Supplementary Fig. 4c). In contrast, cells expressing 
the constitutively active p38δ displayed a significantly suppressed insulin secretion under 
both basal and stimulatory glucose conditions (Fig. 10c). These findings indicate that p38δ is 
a negative regulator of insulin secretion. 
 Enhanced insulin release as a result of Mapk13 loss could be the consequence of an 
increase in the β cell mass, alterations in the pancreatic islet cell distribution and/or enhanced 
insulin production. Immunofluorescence analysis showed normal distribution of pancreatic β 
and α cells in both Mapk13Δ/Δ and Mapk13+/+ mice (Fig. 11a). Quantification of the islet area 
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relative to the whole pancreatic area revealed no differences (Fig. 11b), and total pancreatic 
insulin content as well as total insulin content per islet were equal (Fig. 11c and d).  
 
 
 
Figure 10 Ectopic expression of constitutive active p38δ suppresses insulin secretion in INS1 cells. (a) In 
vitro kinase assay using recombinant histidin (HIS)-tagged ATF-2 as a substrate of immunoprecipitated ectopic 
hemagglutinin (HA)-tagged p38δ. 293 cells were transfected with expression vectors containing HA (lane 1), 
wild type HA-Mapk13 (HA-Mapk13wt) without (lane 2) and with anisomycin (a known activator of p38δ) (lane 
3), constitutive active HA-Mapk13D176A (lane 4) and constitutive active HA-Mapk13F324S (lane 5). After in 
vitro kinase reaction, proteins were separated by SDS-page. In vitro kinase activity was tested by measuring 
phosphorylation of ATF-2 (p-ATF-2) (upper lane). Equal loading of p38d and ATF-2 was confirmed using an 
HA antibody and a HIS antibody, respectively (middle and lower lanes). (b) Western blot to determine ectopic 
and stable expression of HA (lane 1), HA-p38δwt (lane 2) and HA-p38δF324S (lane 3) in INS1 cells. Tubulin 
was used as loading control. (c) Insulin secretion in INS1 cells stably expressing hemagglutinin (HA) tag, HA-
tagged wt p38δ (p38δwt) and constitutive active p38δ (p38δF324S). p38δF324S expressing cells (black bars) 
showed reduced insulin secretion under both basal and stimulatory glucose levels (*p<0.05, unpaired Student’s t 
test), compared to cells expressing either p38δwt (grey bars) or HA (white bars). In all experiments, insulin 
secretion was normalized to total cellular insulin content. 
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 Figure 11 Unaltered islet architecture, islet area and insulin content in Mapk13Δ/Δ mice. (a) Insulin (middle 
left panel, green) and glucagon (middle right panel, red) immunolabeling revealed comparable islet 
characteristics in Mapk13Δ/Δ (lower panels) and Mapk13+/+ (upper panel) mice. DAPI was used to stain nuclei 
(left panel). Merged pictures are provided in the right panels. (b) Quantitative histological assessment of total 
islet area in relation to total pancreatic area. No significant differences in Mapk13Δ/Δ (black bars, n=3) 
compared to Mapk13+/+ (white bars, n=3) could be observed. (c) Total insulin extracted from pancreas 
measured by radio-immuno assays. No significant difference in total insulin content (μg/mg) was detected 
between Mapk13Δ/Δ (black bars, n=3) and Mapk13+/+ mice (white bars, n=3). (d) The mean insulin content per 
isolated islet was also similar in Mapk13Δ/Δ (black bars, n=14) and Mapk13+/+ mice (white bars, n=16). 
 
 This prompted us to address alterations in the insulin secretory pathway205. In the 
absence of Mapk13, insulin secretion from isolated islets was markedly enhanced during 
glucose stimulation (16.7 mM), but also in response to either 20 mM KCl or 100 μM 
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tolbutamide (Fig. 7d), indicating that p38δ acts downstream of glucose metabolism and KATP 
closure. 
 To determine whether the ablation of Mapk13 affects the subsequent Ca2+ influx, we 
measured intracellular calcium concentrations ([Ca2+]i) in response to glucose and KCl in 
islets isolated from Mapk13Δ/Δ and Mapk13+/+ mice. The average [Ca2+]i was similar in the 
two groups of islets both under basal conditions (2.8 mM Glc) and after stimulation by either  
glucose (16.7 mM Glc) or KCl (20 mM in the presence of 2.8 mM Glc) (Fig. 12a and b). 
Likewise, whole-cell Ca2+ currents were comparable in single β cells of Mapk13Δ/Δ and 
Mapk13+/+ littermates (Supplementary Fig. 12c and d). The fact that insulin secretion was 
enhanced in Mapk13Δ/Δ islets despite similar [Ca2+]i levels suggests that p38δ acts 
downstream of the Ca2+ influx. 
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Figure 12 No effect of Mapk13  deletion on [Ca2+]i handling and voltage-gated Ca2+ currents. (a) and (b) 
Representative traces of intracellular calcium  [Ca2+]i in pancreatic islets of wild type (Mapk13+/+) (n=16) (a) 
and Mapk13 null (Mapk13Δ/Δ) mice (n=12) (b) under basal conditions and after stimulation with 16.7 mM 
Glucose and 20 mM KCl. Average responses ±S.E are indicated for basal [Ca2+]i, peak glucose response, 
plateau glucose response, and the peak response to KCl. No significant difference could be observed between 
Mapk13+/+ and Mapk13Δ/Δ islets. (c) Representative Ca2+ current in isolated pancreatic islets of Mapk13+/+ 
(black solid line, n=20) and Mapk13Δ/Δ (grey solid line, n=17) mice evoked by a depolarisation from -70 mV to 
0 mV. Currents are shown together with respective means ±S.E of the peak and sustained currents (measured at 
the end of the pulse). No significant difference was observed between Mapk13+/+ and Mapk13Δ/Δ islets. (d) 
Summary of the average charge entry (derived from the area under the curve during the depolarisation) during 
the 10-ms pulse from -70 mV to 0 mV in Mapk13+/+ (+/+) and Mapk13Δ/Δ (Δ/Δ) β cells. No significant 
difference was observed between Mapk13+/+ and Mapk13Δ/Δ islets.  
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  To address whether exocytosis is enhanced in Mapk13-deficient β cells, we performed 
high-resolution capacitance measurements of exocytosis on single β cells206. A train of 10 
depolarization steps from -70 mV to 0 mV evoked larger responses in p38δΔ/Δ than in control 
β cells, resulting in a 2.1 fold larger increase of membrane capacitance in Mapk13 null 
compared to wild type cells (Fig. 13a and b). Capacitance of cells lacking Mapk13 was also 
higher than that of wild type cells when exocytosis was elicited by dialysing the cell interior 
with a Ca2+/EGTA buffer in order to obtain free Ca2+ concentrations of 1.5 μM, indicating 
that enhanced secretion occurs independently of Ca2+ influx (Fig. 13c). In these experiments, 
the rate of capacitance increase (Δc/Δt) was 50% higher in Mapk13Δ/Δ than in Mapk13+/+ cells 
(Fig. 13d). These results indicate that in pancreatic β cells, p38δ acts as a negative regulator 
of insulin granule exocytosis, downstream of calcium signaling. 
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 Figure 13 Calcium-independent enhancement of exocytosis in Mapk13-deficient pancreatic β cells. (a) A 
train of 10 successive 500 msec depolarizations from -70 to 0 mV increased capacitance (in femtofarad (fF)) in 
both Mapk13-deficient (p38δΔ/Δ) (black bars, n=15) and wild type Mapk13+/+ (white bars, n=10) pancreatic β 
cells. The increase in capacitance evoked by the individual depolarizations was significantly larger (*p<0.05) in 
Mapk13Δ/Δ than in Mapk13+/+ β cells, at depolarization steps 2, 3, 4 and 10. (b) Average cumulative increase of 
capacitance in Mapk13Δ/Δ (black bars) and Mapk13+/+ (white bars) pancreatic β cells (*p<0.05). (c) Capacitance 
increase in picofarad (pF) elicited by intracellular application of 1.5 μM calcium via the recording electrode. 
Values have been normalized to the resting cell capacitance, which was 4.6±0.4 pF, n=8 and 4.6±0.2 pF, n=16, 
in wild type and mutant cells, respectively. Data are presented as the average normalised increase (central line) 
±S.E (shaded areas). The grey curve corresponds to Mapk13Δ/Δ (n=16) while the black curve corresponds to 
Mapk13+/+ (n=8). (d) Steady state average rate of capacitance change for Mapk13+/+ (white bars, n=8) and 
Mapk13Δ/Δ (black bars, n=16) cells measured over a 60 sec period (*p<0.05). 
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 To test whether p38δ activity affects the organization of organelles involved in 
exocytosis, MIN6 cells lacking Mapk13 were compared to their corresponding controls using 
transmission electron microscopy. Inactivation of Mapk13 in MIN6 cells resulted in formation 
of notedly more vesicles at the Golgi network compared to control cells (Fig. 14) All other 
organelles remained unaffected, including insulin-containing granules whose number and 
distribution were similar in Mapk13 null and control cells, in agreement with the comparable 
insulin content of pancreas and islets in Mapk13 null and control littermates (Fig. 11). 
 
 
 
Figure 14 p38δ controls vesicle formation at the trans-Golgi network (TGN). Transmission electron 
microscopy showed that the Golgi apparatus of MIN6 cells stably expressing an empty vector (vector control) 
consisted of stacks of normal thin cisternae. In contrast, Mapk13 shRNA-expressing MIN6 cells (Mapk13 
shRNA) displayed a fragmentation of the Golgi cisternae and increased vesicle formation at the TGN (arrows). 
Size bar 200 nm. 
 
 Budding of secretory vesicles from the Golgi complex occurs through membrane 
fission specifically at the trans-Golgi network (TGN), a key process regulating granule 
trafficking in secretory cells207. To assess whether these alterations mostly affected the TGN, 
we performed immunofluorescence using antibodies against proteins predominantly 
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localizing to the TGN. Inactivation of Mapk13  led to a marked dispersion of giantin in MIN6 
cells (Fig. 15a), as did the absence of Mapk13 in cytospinned primary β cells (Fig. 16a).  
 
 
 
Figure 15 Enhanced membrane fission at the trans-Golgi network (TGN) and increased activity of PKD in 
Mapk13-deficient β cells. (a) Immunofluorescence using antibodies against Giantin (red) and syntaxin 6 (STX6, 
green) showed normal localization of these proteins at the TGN in MIN6 cells expressing the empty vector 
(vector control). In contrast, Mapk13 shRNA expressing MIN6 cells displayed a larger, vesicular distribution of 
Giantin and lack of STX6 localization at the TGN (arrows). DNA was stained with DAPI (blue). Boxes in the 
left column outline the areas that have been magnified in the right panels. Size bar 10 μm. (b) Activity of protein 
kinase D (PKD) was determined by Western blotting using an antibody against activatory phosphorylation sites 
(serines 744 and 748). PKD activity was not detected in MIN6 control cells (vector control) but was evident in 
cells lacking Mapk13 (Mapk13 shRNA) (BG: basal glucose and SG: stimulatory glucose levels). Phorbol 
myristate acetate (PMA)-stimulated INS1 cells were used as a positive control (INS1 PMA). Immunoblotting 
with an antibody against actin was used to determine equal loading of phopho-PKD and total PKD blots. 
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Figure S8 Mapk13 deletion leads to dispersion of the trans-Golgi network proteins giantin and syntaxin 6 
in primary β cells. (a) Immunofluorescence using antibodies against giantin (red) localized this protein in the 
TGN region of wild type Mapk13+/+ (WT) primary β cells. The fluorescence labelling was markedly spread and 
showed a vesicular appearance in cytospinned primary β cells isolated from Mapk13Δ/Δ mice. Nuclear DNA 
was stained with DAPI (blue). Dashed boxes outline the areas that have been magnified in the panels below. Size 
bar 10 μm. (b) Mapk13-deficient (Mapk13Δ/Δ) and wild type Mapk13+/+ (WT) pancreatic islets were analyzed 
by immunofluorescence microscopy using an antibody against the TGN-protein syntaxin 6 (STX6, green). 
Nuclear DNA was stained with DAPI (blue). Dashed boxes outline the areas that have been magnified in the 
panels below. Note that Mapk13Δ/Δ cells show dispersion of STX6. Size bar 10 μm. 
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Figure 17 Mapk13 deletion results in predominant localization of TGN38 to the plasma membrane. (A) 
MIN6 cells stably expressing shRNA against Mapk13 (Mapk13 shRNA) and cells expressing the empty vector 
(vector control) were cultured in the presence of basal (upper panel) or stimulatory glucose levels (lower panel) 
and analyzed by immunofluorescence microscopy using antibodies against TGN proteins TGN38 (red) and 
syntaxin 6 (STX6, green). DNA was stained with DAPI (blue). Note that Mapk13 shRNA expressing cells show 
dislocalization of TGN38 and STX6 (arrows). TGN38 can be found on the plasma membrane in Mapk13 
shRNA-expressing cells (arrows). 
 
 Moreover, syntaxin-6 (STX6), a SNARE protein, which regulates membrane-
trafficking from the TGN to the plasma membrane208-210, failed to localize to the TGN and 
was dispersed throughout the cytoplasm of Mapk13-deficient MIN6 cells (Fig. 15a and Fig. 
17) as well as Mapk13Δ/Δ β cells (Fig. 16b). TGN38, another protein primarily localized to the 
TGN, was found dispersed and translocated to the plasma membrane of MIN6 cells lacking 
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Mapk13, whereas it predominantly localized to the TGN of control cells (Fig. 17). 
Conversely, the expression of the constitutively active p38δ in INS1 cells led to enhanced 
accumulation of STX6 and TGN38 proteins in the TGN (Fig. 18). Moreover, giantin 
immunofluorescence showed that expression of the constitutively active p38δ caused tubular 
protrusions from the Golgi apparatus (Fig. 19). Overall, these data support a specific role of 
p38δ in the organization of the TGN of pancreatic β cells. 
 
 
 
Figure 18 Ectopic expression of constitutively active p38δ results in enlargment of the trans-Golgi 
network. INS1 cells stably expressing hemagglutinin (HA) tag or HA-tagged constitutively active p38δ (HA-
Mapk13F324S) were cultured in the presence of basal (upper panel) or stimulatory glucose levels (lower panel) 
and immunostained with antibodies against TGN proteins TGN38 (red) and syntaxin 6 (STX6, green). Nuclear 
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DNA was stained with DAPI (blue). Expression of p38δF324S led to enhanced and focused staining of TGN38 
and syntaxin 6 indicating enlargment of the TGN. Size bar 10 μm. 
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Figure 19 Ectopic expression of constitutively active p38δ  leads to formation of tubular protrusions from 
the Golgi complex. INS1 cells stably expressing hemagglutinin (HA) tag or HA-tagged constitutively active 
p38δ (HA-Mapk13F324S) were cultured in the presence of stimulatory glucose levels and immunostained with 
antibodies against giantin (red). DNA was stained with DAPI (blue). Boxes in the left column outline the areas 
that were magnified in the panels on the right side. Expression of p38δF324S led to formation of tubular 
protrosions from the Golgi complex (arrows). Size bar 10 μm. 
 
 The protein kinase D (PKD) has evolved as a major player in membrane fission at the 
TGN, which is required to generate transport carriers en route to the plasma membrane211, 212. 
Inhibition of PKD activity blocks secretion by preventing membrane fission and formation of 
tubular Golgi protrusions213, 214. In contrast, PKD overactivation enhances membrane fission 
and increases secretion213, 215. Therefore, we compared phosphorylation of the activatory sites 
of PKD in MIN6 cells lacking Mapk13 and in control cells in response to basal and 
stimulatory glucose levels using Western blotting. No detectable PKD activity could be seen 
in control MIN6 cells, neither under basal nor stimulatory glucose concentrations (Fig. 15b). 
In contrast, a marked activation of PKD was observed in MIN6 cells lacking Mapk13, which 
was further enhanced when these cells were stimulated by glucose (Fig. 15b). We then tested 
whether inhibition of PKD activity in Mapk13Δ/Δ primary β cells reconstituted TGN integrity 
and insulin secretion. Generation of diacylglycerol (DAG) by phosphatidyl-inositol-specific 
phospholipases C (PI-PLCs) at the TGN activates PKD and recruits it to this organelle to 
allow efficient membrane fission. We used the specific PI-PLC inhibitor U73122, which has 
been shown to inhibit PKD activity and transport from the TGN to the plasma membrane24 
and Gö6976, a potent inhibitor of PKD and conventional protein kinases C (PKCs)216. We 
observed that both U73122 and Gö6976 resulted in relocalization of Giantin to the TGN in 
Mapk13Δ/Δ primary β cells, whereas none of the compounds altered the normal localization of 
Giantin in Mapk13+/+ cells (Fig. 20a). Furthermore, pre-treatment with U73122 or Gö6976 
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resulted in similar amounts of insulin secretion in response to 16.7 mM glucose (Fig. 20b). 
Most importantly, peritoneal injections of U73122 decreased the glucose tolerance of 
Mapk13Δ/Δ mice to levels observed in DMSO-treated Mapk13+/+ controls, without modifying 
the glucose tolerance of the latter animals (Fig. 20c).  
 
 
 
Figure 20 PKD inhibition reconstitutes insulin secretion in primary β cells and restores glucose tolerance in 
Mapk13 null mice. (a) Exposure to Gö6976 and U73122 resulted in the relocalization of Giantin to the TGN in 
Mapk13Δ/Δ primary β cells but did not affect its localization in Mapk13+/+ (WT) cells. DNA was stained with 
DAPI (blue). Boxes in the left column outline the areas that have been magnified in the right panels. Size bar 10 
μm. (b) Glucose (16.7 mM)-stimulated insulin secretion was significantly higher from Mapk13Δ/Δ islets (black 
bar, n=5) (*p<0.05) than from Mapk13+/+ islets (white bar, n=5) exposed to DMSO. Both, U73122 and Gö6976 
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reduced insulin secretion of Mapk13Δ/Δ islets (black bars, n=5) (*p<0.05) to the levels observed in Mapk13+/+ 
islets (white bars, n=5). (c) Glucose (2 g/kg b.w.) was injected intraperitoneally after a 16 h fasting, and plasma 
glucose levels were measured at indicated time points. DMSO-treated Mapk13Δ/Δ mice (triangles and dashed 
black line, n=6) showed an improved tolerance to glucose compared to Mapk13+/+ controls (*p<0.05). This 
difference was abolished by treatment with U73122 (crosses and dashed red line, n=6) that reduced the glucose 
tolerance of p38δΔ/Δ mice to the levels observed in Mapk13+/+ (U73122: squares and solid red line, n=5 and 
DMSO: diamonds and solid black line, n=5). 
 
 These experiments demonstrate that enhanced membrane fission at the TGN is fully 
reversible in Mapk13-deficient β cells and thus might represent a critical step enhancing 
insulin secretion and glucose tolerance in Mapk13Δ/Δ mice. Pharmacological inhibition of 
p38δ might represent an innovative and attractive therapeutic approach to enhance insulin 
secretion in diabetic patients. 
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7. Methods  
 
Generation of mice. The Mapk13 floxed mice were generated at Lexicon Pharmaceuticals 
(The Woodlands, TX). The Mapk13 targeting vector was derived using the Lambda KOS 
system217. The Lambda KOS phage library, arrayed into 96 superpools, was screened by PCR 
using primers Mapk13-2 [5’-CCTCGCAGGACCGCCACCAC-3’] and Mapk13-4 [5’-
GGGCGCCAGGTAGGTCTTGG-3’]. The PCR-positive phage superpools were plated and 
screened by filter hybridization using the 114 bp amplicon derived from primers Mapk13-2 
and Mapk13-4 as a probe.  Three pKOS genomic clones, pKOS-50, pKOS-63, and pKOS-70 
were isolated from the library screen and confirmed by sequence and restriction analysis.  
Gene-specific arms (5’-GAACGTACCTGGGCGAGGCGGCAGGT-3’) and (5’-
AGTTACAGCCTTGGAGAACCAGATTCG-3’) were appended by PCR to a yeast selection 
cassette containing the URA3 marker. The yeast selection cassette and pKOS-50 were co-
transformed into yeast, and clones that had undergone homologous recombination to replace a 
346 bp region containing exon 1 with the yeast selection cassette were isolated. This 346 bp 
fragment was independently amplified by PCR and cloned into the intermediate vector pLF-
Neo introducing flanking LoxP sites and a Neo selection cassette (Mapk13-pLFNeo). The 
yeast cassette was subsequently replaced with the Mapk13-pLFNeo selection cassette to 
complete the conditional p38δ targeting vector that has exon 1 flanked by LoxP sites.  The 
Not I linearized targeting vector was electroporated into 129/SvEvBrd (Lex-1) ES cells.  
G418/FIAU resistant ES cell clones were isolated, and correctly targeted clones were 
identified and confirmed by Southern analysis using a 413 bp 5’ external probe (57/58), 
generated by PCR using primers p38δ-57 [5’-GGCACATGGCAAGCACGTATG-3’] and 
Mapk13-58 [5’- CTAATTCTGAGTATAGATCTTTGC-3’], and a 313 bp 3’ internal probe 
(60/59), amplified by PCR using primers Mapk13-60 [5’-CGTGGGTGCTAAGGGTTGAAC-
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3’] and Mapk13-59 [5’- GGTAGCTGGAAGGCAGGAGTG-3’]. Southern analysis using 
probe 57/58 detected a 5.5 Kb wild type band and 3.2 Kb mutant band in Eco RI + Sfi I 
digested genomic DNA while probe 60/59 detected a 15.5 Kb wild type band and 13.8 Kb 
mutant band in Xho I + Sfi I digested genomic DNA. Targeted ES cell clones were 
microinjected into C57BL/6 (albino) blastocysts to generate chimeric animals which were 
bred to C57BL/6 (albino) females, and the resulting heterozygous offspring were bred with a 
protamine-Cre recombinase transgenic line203 to delete exon 1 (Fig. 6). Mice heterozygous for 
exon 1 deletion were backcrossed four times to the C57BL/6 background and intercrossed to 
generate homozygous knockout mice. Genotyping was performed by PCR using following 
primers: Delta-1 (5’-GAGCTACCCAAGACCTACCTG-3’, PGK-162r (5’-
GGATGTGGAATGTGTGCGAGG-3’) and BI5-12 (5’-GCTCAGCTTCTTGATGGCCAC-
3’) yielding a 744 bp band corresponding to the floxed allele and a 560 bp band 
corresponding to the wild type allele; Delta-2 (5’-ACGTACCTGGGCGAGGCGGCA-3’) and 
BI5-12 (5’-GCTCAGCTTCTTGATGGCCAC-3’) yielding a 799 bp wild type band and a 555 
bp band corresponding to the deleted Mapk13 allele. 
 
Animal experiments. For the glucose tolerance test, 8-week-old male mice were fasted for 16 
hr and then injected intraperitoneally with glucose (2 g/kg b.w.). Glucose was measured in 
blood from the tail vein at indicated time points using Accu-Chek Aviva system from Roche. 
In experiments with the PI-PLC inhibitor U73122 (Sigma), mice were injected with U73122 
(2.5 mg/kg b.w.) in DMSO intraperitoneally or DMSO only 1h prior experiment. Insulin 
tolerance tests were performed on 8-week-old ad libitum fed male mice injected 
intraperitonealy with insulin (1U/kg b.w.). Plasma insulin levels during glucose tolerance test 
were measured using an insulin RIA kit (Linco).  
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Western blotting. For Western blotting the following antibodies were used: rabbit-anti-p38δ 
(Santa Cruz Biotechnology) and sheep-anti-p38δ (generous gift of Dr. Ana Cuenda), anti-
phospho-PKD (Cell Signaling Technology), anti-PKD, anti-HIS, anti-hemagglutinin (HA), 
anti-tubulin and anti-Actin (all from Sigma). 
 
Real-time RT-PCR.  RNA was extracted using TRIzol (Invitrogen). cDNA was synthesized 
using the Ready-To-Go You-Prime First-Strand beads (Amersham). Following primers were 
used: Mapk13 forward: 5’-ATGAGCCTCACTCGGAAAAGG-3’, Mapk13 reverse: 5’-
GCATGTGCTTCAAG AGCAGAA-3’, 18S forward: 5’-GTTCCGACCATAAACGATGCC-
3’ 18S reverse: 5’-TGGTGGTGCCCTTCCGTCAAT-3’. 
 
In vitro kinase assay. 293 cells were transfected with a plasmid carrying HA-tagged wt or a 
constitutive active Mapk13 isoforms (D176A and F324S), lysed and incubated with anti-HA 
antibody (Sigma) bound to agarose beads for 2h at 4°C. Immunoprecipitates were washed an 
incubated for 30 min at 30°C in kinase buffer containing 20 μM ATP, 5 μCi [γ-32P] ATP and 
2 mg of recombinant his-tagged ATF-2 (Santa Cruz Biotechnology). 
 
Generation of stable cell lines. INS-1 cells were generated by transfection with the 
pcDNA3.1-HA- Mapk13, pcDNA3.1-HA- Mapk13F324S expression plasmid218 or empty vector 
using Fugene reagent (Roche) and  selected with 500 μg/ml neomycin (Sigma). Knockdown 
of Mapk13 in MIN6 was obtained by lentivirus-mediated transduction of short hairpin against 
Mapk13 RNA (5’-GATCCCCGATGCTGGAGCTGGATGTGTTCAAGAGACACATCCA 
GCTCCAGCATCTTTTTA-3’; 5’-AGCTTAAAAAGATGCTGGAGCTGGATGTGTCTCT 
TGAACACATCCAGCTCCAGCATCGGG-3’) and selection with puromycin (4μg/ml).  
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Islets isolation and insulin secretion. Islets were isolated by collagenase perfusion (1.9 
U/ml) of pancreas and subsequent digestion for 16 min at 37ºC. Islets were handpicked and 
transferred to RPMI1640 media containing 5mM glucose, and maintained for 3h prior to the 
experiments or dispersed in calcium-free solution and then cultured as above. For static 
incubations islets were subsequently pre-incubated for 60 min at 37°C in Krebs-Ringer 
bicarbonate buffer, pH 7.4, supplemented with 0.05% BSA, and 2.8 mM glucose. Following 
pre-incubation, the supernatant was discarded and the islets were incubated in buffer solution 
containing 2.8 or 16.7 mM glucose for 60 min at 37°C. For the rescue experiments islets were 
incubated as described above but in presence of 10 μM of U73122 or 1 μM Gö6976 or 
DMSO. The islets were resuspended in acid ethanol and frozen for insulin content 
measurements. Insulin secretion data were expressed as percentage of pellet. Insulin secretion 
from INS1 and MIN6 cells was performed as described above. Total insulin from pancreas 
was isolated using acid-ethanol extraction. Insulin content was normalized to the total weight 
of the pancreas. 
 
Electrophysiology. Whole cell currents and exocytosis were recorded and analysed using 
EPC-9 patch-clamp amplifiers and the software pulse+pulsefit (Heka Electronic). Exocytosis, 
expressed as an increase in capacitance was elicited by either a train of 10 500 ms 
depolarisations delivered at 1 Hz, from -70 mV to 10 mV or by infusion of a Ca2+/EGTA-
buffer with an intracellular free [Ca2+]i of 1.5 μM. The electrodes were pulled from 
borosilicate glass and had a resistance of 4 to 7. When filled with the electrode solution, the 
access resistance was <15 MΩ and seal resistance > 1 GΩ. β-cells were identified as 
previously described219. In the Ca2+ dialysis experiments, the intracellular solution consisted 
of (in mM) 125 CsCl, 10NaCl, 1 MgCl2, 10 EGTA, 9 CaCl2, 3 Mg-ATP, 0.1 cAMP, 5 Hepes 
(pH 7.15). When exocytosis was triggered by depolarization, the intracellular solution 
contained (in mM) 125 glutamate, 10 CsCl, 10 NaCl, 1 MgCl2, 5 Hepes, 0.05 EGTA, 0.1 
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cAMP and 3 MgATP (pH 7.15). For all experiments, cells were superfused with a solution 
containing 118 NaCl, 20 TEA-Cl, 5.6 KCl, 2.6 CaCl2, 1.2 MgCl2, 25 Hepes, 5 glucose (pH 
7.4). 
 
Measurement of [Ca2+]i. [Ca2+]i was assessed in freshly isolated islets using a dual 
wavelength PTI system (PTI, Monmouth, NJ) fitted on an inverted microscope. Islets were 
loaded with 3 μM fura-2AM in the presence of 0.007% w/v pluronic acid (Invitrogen) for 25 
min at 37ºC. Islets were held in the chamber using a fire polished borosilicate glass pipette. In 
solution composed of (in mM) 140 NaCl, 3.6 KCl, 2 NaHCO3, 0.5 NaH2PO4, 0.5 MgSO4, 5 
Hepes (pH 7.4 with NaOH), 2.6 CaCl2 preheated with temperature controller (TC 324B, 
Warner instrument corporation) at 37ºC. Glucose and KCl were included in the extracellular 
medium as indicated. When KCl was elevated, NaCl was correspondingly reduced. The 
fluorofore was excited at 350 and 380 nm. Emitted light was collected at 510 nm. Ratiometric 
measurements were done at 25 Hz and calibrated as described220. Rmax was measured after 
addition of ionomycin (conc: ~1 μM) in the presence of 10 mM CaCl2 at the end of the 
experiment. Rmin was established by replacing the extracellular solution with 0 mM CaCl2. 
Background was obtained after quenching fura-2 fluorescence with 1 mM MnCl2. 
 
Immunofluorescence. Immunofluorescence for insulin (Linco) and glucagon (Linco) was 
performed on paraformaldehyde-fixed pancreatic sections. Relative islet area was measured as 
percentage of insulin-positive staining sections. Ten different sections per mouse were used. 
Immunofluorescence for syntaxin 6 (BD Bioscience), Giantin (Covance) and TGN38 
(Abcam), were performed on methanol-acetone fixed INS1 and MIN6 cells and primary β-
cells. Islets were dispersed in single cells as described above, incubated in RPMI 1640 
medium containing 5 mM glucose for 2h in the presence or abscence of the PI-PLC inhibitor 
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U73122 (10 μM), the PKC inhibitor Gö6976 (1 μM) or DMSO and then spun onto poly-
lysine-coated slides (700 G for 5 min). 
 
Electron microscopy. For transmission electron microscopy, MIN6 cells have been directly 
fixed on culture dishes in 3% glutaraldehyde buffered with 0.1 M phosphate buffer (pH 7.4), 
embedded in Araldite (Serva, Heidelberg, Germany), cut, and contrasted with uranyl acetate 
and lead citrate. Photographs were taken with a Philips CM 10 or EM 300 electron 
microscope. 
 
Statistical analysis. Data are presented as mean values ± SE. Statistical significance was 
calculated using an ANOVA with post-hoc Tukey’s test and Student unpaired t test, 
respectively. Significance was accepted at the level of p<0.05. 
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7. Discussion 
 
 Three major groups of the mitogen activated protein kinase (MAPK) family have been 
identified in mammals: extracellular signal regulated kinases (ERKs), c-Jun N-terminal 
kinases (JNKs) and p38 MAPKs221, 222. An extensive research activity defined particular 
functions for MAPK in immunity223. More recently, JNK has been discovered to be a critical 
regulator of obesity and insulin resistance4.  
  Similar to the JNK pathway, the closely related p38 signaling cascade appears to 
mediate various molecular events in response to inflammatory and metabolic stimuli in 
different cell types and organs. 
 Four isoforms of p38 MAPK encoded by four different genes have been identified: 
p38α126, p38β127, p38γ 128 and p38δ129. Activation of p38 occurs via dual phosphorylation of 
the conserved TGY motifs by the MAPK kinases, MKK6 and MKK3117. Over the last decade, 
various substrates of p38 have been identified. Moreover, innumerable p38 expression and 
activation studies have been conducted in animal disease models, in patients and in vitro 
models. Although some of the available data seem to be controversial, these studies suggest 
that p38 represents a key regulator of many basic biological processes such as proliferation, 
differentiation, stress response, development, tumorgenesis, inflammation and apoptosis and 
thus could be involved in several diseases9, 224. However, the requirement of p38 in all of 
these processes in vivo and even in vitro and the specific roles of p38 isoforms are largely 
unknown.  
 In our study, we showed that unlike other isoforms of the p38 family, the p38δ 
expression pattern is largely restricted to pancreatic islets and exocrine pancreas. Moreover, 
expression of p38δ could not be detected in other organs involve in regulation of glucose 
homeostasis. This specific pattern of expression prompted us to investigate p38δ function in 
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pancreatic β cells and regulation of glucose homeostasis. To address these questions, we 
generated p38δ knockout mice. Consistently with previous reports, these mice were viable, 
fertile and did not show any obvious phenotype184. However, p38δ-deficient mice showed 
improved glucose tolerance due to enhanced insulin secretion caused by increased insulin 
granule exocytosis from pancreatic β cells. p38δ seems to specifically regulate glucose 
homeostasis by regulation of insulin release since the levels of glucagon, another key 
hormone involved in regulation of serum glucose levels, which is specifically secreted by α 
cells in the pancreatic islet, are not affected by deletion of this kinase. Since enhanced activity 
of pancreatic β cells has a suppressive effect on glucagon secretion225, we did not fully 
exclude that α cells lacking p38δ also show enhanced secretion and that enhanced activity of 
β cells observed in these mice would mask this effect. For this purpose, α cells should be 
specifically isolated and tested for their secretion capacity. Alternatively, this might indicate 
inhibitory mechanisms mediated by p38δ  are present or necessary only in certain secretory 
cell. Our experiments also demonstrate that deletion of p38δ does not affect peripheral insulin 
sensitivity, which is in line with the lack of expression of p38δ in peripheral insulin-
sensitizing organs. We can also not exclude whether p38δ mediates the hypothalamic 
regulation of glucose levels226. In fact, a recent study indicates that a subset of hypothalamic 
pro-opiomelanocortin (POMC) neurons regulate peripheral glucose disposal in response to 
elevated glucose levels. Moreover, POMC neurons are sensing glucose utilizing similar 
molecular mechanisms as reported for pancreatic β cell227, therefore a possible involvement of 
p38δ in hypothalamic regulation of glucose homeostasis should be investigated in future. 
 Since p38δ not only is expressed in pancreatic β cells but also is highly abundant in 
neutrophils (Ittner A. et al. unpublished data), we also studied the function of this kinase in 
neutrophils, which, as the pancreatic β cells, represent specialized granulated secretory cells. 
Intriguingly, neutrophils lacking p38δ likewise show hypersecretory features (enhanced 
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degranulation), which affects their recruitment to inflammatory sites and overall migratory 
capacity, highlighting the importance of p38δ in neutrophil-dependent innate immunity (Ittner 
A. et al. unpublished data). 
 Most intriguingly, pancreatic β cells (primary cells as well as cell lines) lacking p38δ 
showed a very particular and consistent phenotype in the trans-Golgi network (TGN). By 
immunofluorescence and transmission electron microscopy, we have found that the TGN 
formed markedly more vesicles and that several TGN-resident proteins are constitutively 
dispersed, a phenomenon, which typically occurs when membrane fission at the TGN is 
enhanced to trigger more efficient vesicle transport from the TGN to the plasma membrane. 
Most important in this context, these mechanisms have been shown to be crucial to enhance 
regulated secretion of cargo proteins (i.e. neurotensin secretion from neuroendocrine cells)212, 
228, 229 and therefore they might explain the observed enhanced insulin secretion in the absence 
of p38δ. To further corroborate this hypothesis, we considered recent exciting studies 
(published in Cell, Science, Journal of Cell Biology and Nature Cell Biology) that 
demonstrated that membrane fission at the TGN is in fact tightly regulated at the molecular 
level. It is now established that protein kinase D (PKD) is specifically required to promote 
membrane fission at the TGN212-215, 230-232. Consistently, we see PKD constitutively activated 
in β cells lacking p38δ. Most importantly, we were able to demonstrate that inactivation of 
PKD, using inhibitors, fully restores enhanced membrane fission at the TGN in p38δ-deficient 
cells and reconstitutes normal insulin secretion in islets lacking p38δ as well as glucose 
tolerance in p38δ null mice. Overall, we present strong evidence that p38δ is an important 
negative regulator of insulin secretion that links PKD-dependent TGN membrane fission in 
pancreatic β cells to insulin secretion and glucose homeostasis. 
PKD itself is activated by specific upstream signaling events: Upon stimulation of 
cells, most probably mediated by a G protein coupled receptor (GPCR), the GTP-binding 
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protein β1γ2 subunit translocates to the membrane of the TGN and activates phosphatidyl-
inosytol phopholipase C β3 (PI-PLCβ3), which results in generation of a second messenger 
molecule, diacylglycerol (DAG). DAG is required to activate protein kinase C η (PKC η)  
which in turn recruits PKD to the membrane of TGN. Once recruited to the TGN, PKC 
η phosphorylates PKD at the activatory sites215 (Fig. 21). We have shown that inhibition of 
PKD activity using a phosphatidyl-inosytol phopholipases C (PI-PLCs) specific inhibitor 
U73122 or Gö6976, a potent inhibitor of PKD and conventional PKC isoforms, restores 
membrane fission from TGN and insulin secretion in p38δ-deficient β cells to the levels 
observed in wild type cells. Moreover, inhibition of PKD in vivo in p38δ knockout mice using 
U73122 inhibitor decreased glucose tolerance to levels observed in wild type animals, 
whereas the same substance had no effect on glucose tolerance in wild type mice. Taken 
together, these data suggest that p38δ-dependent suppression of membrane fission at the TGN 
and insulin secretion from pancreatic β-cells is achieved by suppression of PKD activity. 
 However, the exact molecular mechanisms of p38δ-dependent suppression of 
PKD activation is unclear. The fact that inhibition of PI-PLC in p38δ-deficient cells is 
sufficient to rescue the phenotype, might suggest that p38δ rather acts upstream of PI-PLC, 
for example by desensitizing the GPCR to its ligand, by blocking the action of the Gβγ 
subunit or by directly inhibiting PI-PLC action. Still, it is also possible that p38δ directly 
inhibits PKC η or PKD. Eventually, full activation of PKD or PKC η might require both 
activation by DAG but also abolition of a direct p38δ-dependent inhibitory effect on PKC 
η and or PKD (Fig. 1). The second hypothesis is supported by the fact that activation of PKD 
is notedly more pronounced in the presence of stimulatory glucose levels when the cellular 
content of DAG increases only in the absence of p38δ. In wild type cells, despite the fact that 
DAG generation is enhanced in pancreatic β cells upon glucose stimulation1 PKD activity and 
thus membrane fission is kept at very low levels, most likely by p38δ. This would also imply 
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that p38δ sets a threshold to control membrane fission at the TGN. In our laboratory, we 
recently obtained strong biochemical data, which fully support a direct regulation of PKD 
activity by p38δ (Formentini I et al. unpublished data). p38δ physically interacts with PKD 
and directly phosphorylates it at specific serine residues (Ser 397 and Ser 401), both of which 
represent conserved p38 MAPK phosphorylation sites. Future experiments will be conducted 
to analyze these phospho-sites functionally regarding their potential inhibitory nature. 
Another key question remains: What are the upstream factors/pathways regulating 
p38δ activity? And along the same line, what are the precise physiologic conditions in which 
p38δ activity has to be diminished/enhanced to allow/prevent PKD to exert membrane fission 
at the TGN? Although previous studies established several pro-inflammatory agents, which 
activate p38δ129, other physiological stimuli, which may lead to activation or deactivation of 
p38δ are not yet identified. In our study, we also showeded that the kinase activity of p38δ is 
sufficient to inhibit insulin secretion and vesicle fission from the TGN, since ectopic 
expression of constitutive active but not the wild-type form of p38δ suppressed the release of 
insulin and fission of vesicles from TGN. Potential activators of p38δ should decrease the 
release of insulin. Several agents and physiologic conditions may serve as potential factors 
activating p38δ. Among others, low glucose levels and the release of sympathetic 
neurotransmitters such as norepinephrine or catecholamines (i.e. under fasting conditions) 
should be considered. In fact, enhanced insulin secretion in p38δ knockout mice can be 
predominantly seen after fasting them (data not shown), while ad libitum fed mice show 
almost no differences in insulin release. On the other hand, it is possible that in pancreatic β 
cells, a certain pool of p38δ is constitutively active and stimulation with insulinotropic agents 
such high glucose, FFA, GLP-1 or acetylcholine could result in p38δ inactivation and more 
efficient fission of secretory granules at the TGN. Interestingly enough, many of the factors 
mentioned above act through GPCRs, the latter of which, although unidentified yet, has been 
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proposed to regulate the activity of PKD. In particular, it should be mentioned here that 
acetylcholine, binding mainly to M3 muscarinic receptors, activates PI-PLC to generate DAG 
and to enhance insulin secretion233. Experiments with these agents and conditions in the 
absence or presence of p38δ/PKD have to be conducted in the near future. 
 Several lines of evidence suggest that activation of multiple pathways, which initially 
enhance insulin secretion, in the long term (i.e during the state of peripheral insulin 
resistance) might lead to pancreatic β cell failure15, 83, 96, 99. In our study, we so far have used 
mostly 8 to 12 weeks old animals, which did not reveal apparent signs of pancreatic β cell 
failure. However, it will be important to test, how pancreatic β cells lacking p38δ behave in 
the settings of type-2 diabetes. We will therefore cross the knockout mice with genetic models 
of obesity-related insulin resistance and also challenge them with a high-fat diet. 
  In conclusion, in our study, we identified for the first time an in vivo function for the 
non-canonical p38 isoform p38δ. We showed that p38δ suppresses insulin secretion from 
pancreatic β cells and therefore glucose tolerance. Increased insulin secretion from pancreatic 
β cells in the absence of p38δ was most probably caused by increased vesicle fission from the 
TGN membrane and was mediated by overactivation of PKD, since pharmacological 
blockage of PKD restored insulin secretion from p38δ-deficient islets to wild type levels. 
 Given the fact that p38δ has a specific expression pattern and its deletion in mice does 
not lead to any obvious detrimental health consequences, specific inhibition of p38δ might 
represent an attractive strategy to treat diabetic patients. However, additional experiments 
unraveling the exact function of this kinase in the models of type-2 diabetes need to be 
conducted. 
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 Fig. 21 Regulation of TGN membrane fission and possible targets of p38δ. Upon stimulation of cells, most 
probably mediated by a G protein coupled receptor (GPCR), GTP-binding protein βγ subunit translocates to the 
membrane of the TGN and activates phosphatidyl-inosytol phopholipase C β3 (PI-PLCβ3) resulting in 
generation of second messenger molecule, diacylglycerol (DAG) and subsequent activation of protein kinase C η 
(PKC η) and PKD. PKD mediates TGN membrane fission through not yet fully identified mechanisms. One 
possible target might be phosphatidylinositol 4-kinase IIIbeta (PI4KIIIbeta)234.  Possible targets of p38δ are 
indicated with dashed lines. As indicated in the text, we favour a model, in which p38δ directly suppresses the 
activity of PKD. 
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